This is a preview of subscription content, log in via an institution to check access.
Reference
Giannouchos TV, et al. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clinical Drug Investigation : 13 Jul 2019. Available from: URL: https://doi.org/10.1007/s40261-019-00827-z
Rights and permissions
About this article
Cite this article
Erenumab in chronic migraine: better outcomes at high cost. PharmacoEcon Outcomes News 833, 20 (2019). https://doi.org/10.1007/s40274-019-6084-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6084-2